Journal article
Natural history of diabetic macular edema and factors predicting outcomes in sham-treated patients (MEAD study)
Young Hee Yoon, David S Boyer, Raj K Maturi, Francesco Bandello, Rubens Belfort, Albert J Augustin, Xiao-Yan Li, Zhanying Bai, Yehia Hashad, Suel Abujamra, James Acton, Fareed Ali, Andrew Antoszyk, Albert J Augustin, Carl C Awh, Adiel Barak, Karl Ulrich Bartz-Schmidt, Caroline R Baumal, Rubens Belfort, Muna Bhende Show all
GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY | SPRINGER | Published : 2019
Abstract
PURPOSE: To describe the natural history of diabetic macular edema (DME) with respect to best-corrected visual acuity (BCVA) and central retinal thickness (CRT) outcomes and to identify baseline patient characteristics and systemic factors associated with improvement or worsening of outcomes in sham-treated patients. METHODS: The study population was sham-treated patients (n = 350) in the 3-year MEAD registration study of dexamethasone intravitreal implant for treatment of DME. Patients had center-involved DME and received sham intravitreal injections in the study eye at ≥ 6-month intervals. Potential prognostic factors for outcomes were evaluated using multiple linear regression analysis. R..
View full abstractGrants
Funding Acknowledgements
This study was sponsored by Allergan plc, Dublin, Ireland. Y.H. Yoon, D.S. Boyer, R.K. Maturi, F. Bandello, and R. Belfort Jr. are consultants to Allergan. A.J. Augustin has received research support and speaker fees from Allergan. X.-Y. Li, Z. Bai, and Y. Hashad are employees of Allergan. The authors have full control of all primary data and they agree to allow Graefe's Archive for Clinical and Experimental Ophthalmology to review their data upon request.